Strong demand for a product doesn’t automatically translate into business success, especially within the nuanced cannabis sector. While general retail grapples with inflation, rising labor and rent expenses, and shifting consumer habits, marijuana operators face a distinct set of challenges that can undermine even robust sales figures.
The First Citizens February 2026 State of the Cannabis Industry report notes that, despite macro‑level pressures such as evolving policy and inflation, “consumer demand for both hemp and marijuana products remains strong throughout the U.S.” Yet the industry recorded its first revenue decline after a decade of growth. According to the same report, 2024 sales reached $30.1 billion, while 2025 revenues fell to an estimated $28.6–$29.6 billion. Unit volumes stayed steady, indicating that falling average prices—driven by deflationary pricing pressures—were the primary cause of the downturn. Roughly one‑third of operators reported 2025 revenue drops, prompting cost‑cutting measures and layoffs.
Beyond these economic headwinds, cannabis companies must contend with continual regulatory shifts at both federal and state levels, adding another layer of uncertainty to an already volatile market.
Atlantic Medicinal Partners (AMP) abruptly closes all locations amid lawsuits
Medical and recreational cannabis company Atlantic Medicinal Partners (AMP) has suddenly shut down all three of its locations, a move reported by Hemp Gazette and corroborated by the Worcester Business Journal. The closures include the Fitchburg dispensary and cultivation facility, as well as retail sites in Salem and Brockton, Massachusetts.
The shutdown follows two lawsuits seeking a combined $6.11 million in damages related to alleged unpaid debt and loan obligations.
Lawsuits against Atlantic Medicinal Partners
-
The landlord lawsuit: The property owner where AMP cultivated and sold its products claims the company owes $112,000 in unpaid rent and more than $64,800 in water and sewer bills to the City of Fitchburg. The landlord is suing for $3.54 million, alleging that AMP’s executives misrepresented the company’s financial stability. As part of the proceedings, the judge ordered AMP to post a $300,000 bond specifically for its unpaid taxes and water bills in Fitchburg.
-
The investor lawsuit: On May 6, 2026, Victoria Waters filed suit in Middlesex Superior Court to enforce a $2.57 million arbitration award granted to her in April 2026. The dispute originates from a $1 million, five‑year loan Waters extended to AMP in 2019, which carried a 15 % annual compounding interest rate and matured in March 2024. Waters alleges that AMP defaulted by failing to repay both the principal and the accrued interest. Source: Hemp Gazette
The 11th largest cannabis company in central Massachusetts
Atlantic Medicinal Partners, a vertically integrated cannabis operator, was founded in September 2020 by CEO Steve Perkins, COO Jeff Perkins, and business partner Frank Cieri. The company’s inaugural facility replaced a former Lego manufacturing plant in Fitchburg and combined cultivation with dispensary sales. AMP later expanded its footprint to Salem and Brockton, all of which are now closed.
The firm’s “seed‑to‑sale” model—where most flower and derivative products are cultivated and processed in‑house—helped differentiate it from neighboring dispensaries. At its Fitchburg location, consumers could find:
-
Pre‑packed chillum pipes from notable Massachusetts growers such as Ace Weidman’s, Nature’s Heritage, Revolutionary Clinics, and In Good Health
-
Hash formulas including distillate, RSO (Rick Simpson Oil), and shatter
-
Edibles, notably chocolate and gummies
According to data from the Worcester Business Journal Research Department, AMP ranked as the 11th largest cannabis company in central Massachusetts as of Q2 2025, employing roughly 50 workers at that time.
AMP’s closure and accompanying debt troubles illustrate the broader financial pressures confronting other operators in the region.
Related: Target expands controversial beverage line sales
What the AMP closure means for the cannabis industry and consumers
The sudden shutdown of AMP is not an isolated incident in central Massachusetts. Hemp Gazette reports that several other marijuana businesses in the area have either ceased operations or entered receivership due to financial strain. As of April 16, 2026, the Cannabis Control Commission recorded 31 cannabis licenses under receivership, underscoring sector‑wide stress.
Decades of stigma mean that every move by a licensed cannabis firm is scrutinized intensely; a misstep can reverberate across the entire market. Economists warn that illicit operators, unburdened by compliance costs, can easily undercut legal businesses by lowering prices, thereby exacerbating deflationary pressures—a dynamic highlighted in the Journal of Economic Behavior and Organizations article “Weeding out the dealers? The economics of cannabis legalization.”
Consumers also feel the impact. When legal dispensaries disappear, patients and recreational users may turn to unregulated sources, increasing the risk of exposure to untested and potentially harmful products. A study conducted by researchers at Arizona State University, published in Environmental Health Perspectives, analyzed illicit cannabis samples seized by law enforcement and found alarming levels of dangerous toxins and biological agents that are prohibited in the legal market. Lead researcher Maxwell Leung, an ASU assistant professor, stated, “The contaminants in illicit cannabis represent a public health risk that needs to be addressed.”
Related: Another mall retailer quietly closes 7 stores, plans more
This story was originally published by TheStreet on May 18, 2026, where it first appeared in the Retail section. Here
